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ABSTRACT
Introduction The current evidence on the efficacy of 
antibiotic- loaded bone cement (ALBC) in reducing the 
risk of periprosthetic joint infections (PJI) after primary 
joint reconstruction is insufficient. In several European 
countries, the use of ALBC is routine practice unlike in the 
USA where ALBC use is not approved in low- risk patients. 
Therefore, we designed a double- blinded pragmatic 
multicentre register- based randomised controlled non- 
inferiority trial to investigate the effects of ALBC compared 
with plain bone cement in primary total knee arthroplasty 
(TKA).
Methods and analysis A minimum of 9,172 patients 
undergoing full- cemented primary TKA will be recruited 
and equally randomised into the ALBC group and the 
plain bone cement group. This trial will be conducted in 
Norwegian hospitals that routinely perform cemented 
primary TKA. The primary outcome will be risk of revision 
surgery due to PJI at 1- year of follow- up. Secondary 
outcomes will be: risk of revision due to any reason 
including aseptic loosening at 1, 6, 10 and 20 years of 
follow- up; patient- related outcome measures like function, 
pain, satisfaction and health- related quality of life at 1, 6 
and 10 years of follow- up; risk of changes in the microbial 
pattern and resistance profiles of organisms cultured in 
subsequent revisions at 1, 6, 10 and 20 years of follow- 
up; cost- effectiveness of routine ALBC versus plain bone 
cement use in primary TKA. We will use 1:1 randomisation 
with random permuted blocks and stratify by participating 
hospitals to randomise patients to receive ALBC or plain 
bone cement. Inclusion, randomisation and follow- up will 
be through the Norwegian Arthroplasty Register.
Ethics and dissemination The trial was approved by the 
Western Norway Regional Committees on Medical and 
Health Research Ethics (reference number: 2019/751/
REK vest) on 21 June 2019. The findings of this trial will 
be disseminated through peer- reviewed publications and 
conference presentations.
Trial registration number NCT04135170.
Strengths and limitations of this study
 ► To our knowledge, this is the first large pragmatic 
multicentre register- based randomised controlled 
non- inferiority trial designed to investigate the ef-
fects of routine antibiotic- loaded bone cement use in 
primary total knee arthroplasty in preventing subse-
quent revision due to periprosthetic joint infections.
 ► Register- based randomised controlled trial (R- RCT) 
represents new possibilities, pairing the power of 
randomisation with the simplicity of a quality reg-
ister to detect clinically important differences in pa-
tient outcomes.
 ► R- RCT will facilitate large pragmatic interventional 
trials with adequate statistical power and low cost 
in the real- world setting.
 ► In this trial, the work load on the patient and the 
surgeon is minimal, and all follow- up is done elec-
tronically via web- based solutions through the 
Norwegian Arthroplasty Register, a well- established 
register, with high national coverage and good re-
sponse rate.
 ► The limitation of this trial is that the surgeons are not 
blinded, which would yield bias, however, we believe 
the primary endpoint of this trial is not likely to be 
influenced by the surgeon knowledge of the cement 




pril 13, 2021 at H










pen: first published as 10.1136/bm







pril 13, 2021 at H










pen: first published as 10.1136/bm







pril 13, 2021 at H










pen: first published as 10.1136/bm







pril 13, 2021 at H










pen: first published as 10.1136/bm







pril 13, 2021 at H










pen: first published as 10.1136/bm




2 Leta TH, et al. BMJ Open 2021;11:e041096. doi:10.1136/bmjopen-2020-041096
Open access 
INTRODUCTION
Total knee arthroplasty (TKA) is an effective treatment for 
degenerative knee joint disease.1–3 The incidence of TKA 
is increasing worldwide4 and projected to reach 5 million 
by 2030.5 Despite the numerous perceived improvements 
in perioperative antimicrobial procedures, periprosthetic 
joint infection (PJI) following TKA remains a serious 
complication for patients and a burden for the health-
care system.6 7 PJI is one of the most frequent causes of 
TKA revision surgery accounting for more than 15% of 
all revisions.8 9
PJI may result in a long hospital stay, increased risk 
of readmission and poor patient outcomes including 
decreased function and diminished quality of life. In 
worst case, it may lead to amputation or even death.10 11 
The cost burden due to PJI is almost twice as high as those 
without PJI and the cost per PJI- related admission being 
around US$80,000 in the USA.11 12
To reduce the risk of PJI, antibiotic- loaded bone 
cement (ALBC) has been widely used over the last 40 
years.13 14 Therefore, the use of ALBC is standard prac-
tice in many European countries today.6 15 16 However, 
in the USA, the use of ALBC is only approved for revi-
sion of infected arthroplasty and ALBC is not licensed 
for prophylactic use in primary arthroplasty for low- risk 
patients.15 17 In Australia, the use of ALBC in arthroplasty 
surgery depends on the preference of the surgeons and 
hospitals.18
The use of ALBC and its efficacy in reducing PJI are 
persistently debated in the literature.7 15 16 19–53 The 
supporters of routine ALBC- use in primary arthroplasty 
claim that it reduces the risk of PJI7 16 35 38 41 43 46 52 and 
consequently reduces patient suffering and costs without 
noticeable side effects. However, the opponents claim 
that the antibiotic in ALBC weakens the mechanical 
properties of cement and thus, increase the risk of 
aseptic loosening,54 55 systemic toxicity or allergic reac-
tion,28 32–34 56 bacterial resistance24–27 and consequently 
increases patient suffering and cost.15 20 53 57 58 Up to 8.4% 
of antibiotics in ALBC are released within 6 hours after 
surgery, followed by a low- dose release over months, 
which may be below both the minimum bactericidal 
concentration and the minimal inhibitory concentration 
(MIC)27 28 Prolonged exposure to antibiotic at a lower 
concentration than MIC could lead to the development 
of mutational resistance in bacteria or selection of resis-
tant strains.59 Thus, the theoretical benefit of prophy-
lactic ALBC in reducing the risk of PJI should be weighed 
against its potential adverse effects.
The conclusions from both observational and 
randomised controlled trial studies on ALBC are incon-
sistent.16 17 39 40 42 43 45 60 Chiu et al60 reported a significant 
reduction in risk of PJI by use of ALBC in primary TKA 
in patients with diabetes mellitus (high- risk patients). 
A study from Spain39 reported that the use of erythro-
mycin and colistin- loaded cement in TKA did not lead 
to a reduction in the incidence of infection. Namba et 
al42 even reported a higher rate of infection at 1 year in 
the group treated with ALBC compared with plain bone 
cement (1.4% vs 0.7%). Qadir et al17 also reported that 
the use of ALBC did not prevent PJI after primary TKA, 
even in high- risk patients. Several meta- analyses and 
systemic reviews studies have concluded that the use of 
ALBC versus plain bone cement did not decrease the rate 
of deep infections in TKA.36 37 48–50 52
In Norway, antibiotic resistance is a limited but 
emerging problem. Antibiotic stewardship is important to 
ensure future effectiveness of antibiotics.61 Thus, in 2015, 
the Norwegian government set goals to reduce antibiotics 
use in humans by 30% by 2020.62 63
The current evidence on the effectiveness of ALBC in 
reducing the risk of PJI after arthroplasty is insufficient28 
and previous studies on ALBC use have indeed called for 
large, prospective, and preferably multicentre studies to 
justify routine use of ABLC in primary arthroplasty.19 20 
In Norway, the proportion of ALBC use in hybrid or fully 
cemented primary TKA increased from around 70% in 
1994 to nearly 100% in 2019.64 Without a definitive trial, 
patients will be exposed to a treatment of uncertain effi-
cacy that may drive antibiotic resistance at a higher imme-
diate and future cost.
Register- based randomised controlled trial (R- RCT) 
represents new possibilities, pairing the power of rando-
misation with the simplicity of a quality register to detect 
clinically important differences in patient outcomes.65 66 
R- RCT may facilitate large pragmatic interventional trials 
with adequate statistical power and low cost in the real- 
world setting.65
Therefore, we present a trial protocol for a large prag-
matic multicentre register- based randomised controlled 
non- inferiority trial aiming to investigate the effects of 
ALBC compared with plain bone cement in primary 
TKA. We hypothesise that: (1) Plain bone cement is non- 
inferior to ALBC in risk of revision due to PJI following 
primary TKA; (2) Patient reported outcome measures 
(PROMs) of patients operated with ALBC in primary TKA 
are similar compared with that of patients operated with 
plain bone cement; (3) Routine use of ALBC in primary 
TKAs does not result in a change in the microbial pattern 
and resistance profiles of organisms cultured in subse-
quent revision due to PJI and (4) Routine ALBC use is as 
cost- effective as plain bone cement use in primary TKA.
MATERIALS AND ANALYSIS
Study design
This is a double blinded, multicentre, register- based 
randomised controlled non- inferiority trial. The study 
will include patients undergoing full- cemented primary 
TKA. The patients will be randomised to TKA with 
either ALBC or plain bone cement through the Norwe-
gian Arthroplasty Register (NAR). Our trial protocol 
follows the Standard Protocol Items: Recommendations 
for Interventional Trials reporting guideline for clinical 
trials.67 A summary of the trial design is presented graph-
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Study setting and population
All Norwegian hospitals that perform cemented TKAs 
routinely are invited to participate in this study. In Norway, 
nearly 6,000 TKA surgeries are performed annually and 
over 80% them are cemented.68 All patients undergoing 
full- cemented primary TKA are eligible for participation 
irrespectively of the diagnosis leading to TKA. The indi-
cations for TKA and routines during the patient’s stay 
at the hospital will be as usual practice at each hospital. 
Exclusion criteria will be; any history of infection in the 
knee, a need for fully stabilised or hinged TKA, a history 
of allergy to the antibiotics used in the cement, inability 
or not willing to consent for inclusion in NAR or the trial, 
and participation in other studies that might have phar-
macological interaction with this trial.
Definitions
Revision is defined as the removal, addition and/or 
exchange of part of an implant or the whole implant. 
‘Second revision’ is defined as a subsequent revision. 
Since the NAR records revision surgery due to deep infec-
tion, PJI in ALBA trial means only surgically treated PJI 
and excludes superficial infections and infections treated 
only by antibiotics.
Informed consent
An orthopaedic surgeon or nurse will introduce the trial 
to the patients. Patients fulfilling the inclusion criteria 
will receive verbal and written information about the 
trial prior to surgery and will be asked to sign a consent 
form (online supplemental file 1—informed consent- 
Norwegian version). We will inform the patients that 
participation in the study is entirely voluntary and any 
decision they make will not influence their future health-
care. Participants will also be informed of their right to 
withdraw from the trial whenever they desire without any 
reason they need to supply for such decision, however, 
their data acquired prior to withdrawal will be maintained 
in the study database and included in the analysis to avoid 
bias.
Randomisation and allocation concealment
Both the randomisation and reporting will be web based, 
governed from the NAR. The randomisation will be done 
directly in a web- based registration system before the start 
of the surgery. We will use 1:1 randomisation with random 
permuted blocks (of 4, 6 or 8) and stratify by participating 
hospitals to randomise patients to receive ALBC or plain 
bone cement.69 70 The data that will be collected is the core 
dataset in the NAR: patient identity, date of operation, indi-
cation for primary TKA, type of implant and other surgery- 
related factors. Information on patient- related factors like 
sex, age and comorbidities is also registered. The unique 
social security number of each Norwegian inhabitant links 
the primary TKA to any subsequent revisions or reop-
eration, and to the National Population Register, which 
provides information on death and emigration. Revision 
is defined as the removal, addition and/or exchange of 
part of an implant or the whole implant, whereas, reopera-
tion is defined as surgery associated with the TKA without 
removing, adding and/or exchanging prosthesis parts. 
The NAR records both reoperations and revision surgery 
due to deep infection, but not conservatively/suppres-
sive treated PJI. Hence, only surgically treated PJI will be 
included in this trial. The surgeon fills in the register form 
immediately after surgery. PROMs will be collected elec-
tronically per the NAR standard routine. There will be 
manual back- up solutions in the case of temporal techno-
logical problems with randomisation or reporting.
Figure 1 Flowchart (summary of trial design). ALBC, antibiotic- loaded bone cement; NAR, Norwegian Arthroplasty Register; 
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Every hospital participating in this trial needs to have 
both types of cement (with and without antibiotics) avail-
able at all times. The catalogue number of cement used 
in each operation is reported by scanning the barcode 
on the package of the used cement. If the cement used 
does not match the cement drawn by randomisation, 
the registration will still be used to perform intention to 
treat- analyses and as treated- analyses. The surgical proce-
dures are performed according to the protocols at each 
hospital.
In case of any revision, the surgeon will fills in a revi-
sion report, similar to the report after primary TKA. The 
surgeon will then report on the indication for revision 
surgery. In the case of a reported revision due to deep 
infection or aseptic loosening, additional information on 
biochemical and bacteriological findings will be collected 
to validate the diagnosis of PJI and to collect information 
on bacteriological findings and antimicrobial resistance.
Blinding
Confounding and selection bias that might affect observa-
tional studies will be minimised through randomisation; 
however, randomisation does not prevent subsequent 
biased assessment of outcomes.71 Patients and data 
analysts will, therefore, be blinded in this trial. Blinding 
of the surgeon will not be possible because the surgeon 
recognises the cement type and has to document the type 
of cement in the electronic registration form. We believe 
the primary endpoint of this trial is not likely to be influ-
enced by the surgeon knowledge of the cement used in 
the index surgery. The data analyst will be blinded for the 
group allocation until the entire trial analysis has been 
completed to minimise the risk of bias that may be intro-
duced during the statistical analysis because of the selec-
tive use and reporting of statistical tests.71
Sample size and statistical power
Earlier register study showed that ALBC and plain bone 
cement had 1% and 1.5% risk of revisions for deep infec-
tion 1 year after primary total hip arthroplasty, respec-
tively.7 This trial is a non- inferiority trial72 73 assuming 
a 1- year revision rate of 1% following primary TKA 
with ALBC. To show the non- inferiority of plain bone 
cement to ALBC with respect to revision due to PJI 1 year 
after primary TKA, with at least 80% power, and a non- 
inferiority margin of 0.15 percentage points at a one- 
sided significance level of 0.025, 9,172 patients (4,586 in 
each group) would need to be enrolled.
Based up on the non- inferiority margin of 0.15, the 
number needed to harm will be 667 (100 divided by 
0.15). In other words, we assume that around 670 patients 
needed to undergo primary TKA surgery with plain bone 
cement to cause harm (revision due to PJI) in one patient 
that would not otherwise have been harmed.
Interim analysis
Interim analyses will be carried out after 1,000 and 6,000 
patients have been enrolled. If we consider stopping the 
trial early, the O’Brien- Fleming stopping rule will be 
used to declare a statistically significant difference in the 
primary outcome between the two groups.74 75 The trial 
steering committee will based on the interim analyses 
make a recommendation to the Norwegian National Advi-
sory Unit on Arthroplasty and Hip Fractures’ Steering 
Committees, as to whether the trial should be stopped 
early or not. This recommendation will also take other 
sources of evidence such as secondary outcomes and 
safety data into consideration.
Planned intervention
The patients randomised to ALBC (control group) 
will receive bone cement with antibiotics and those 
randomised to plain bone cement (experimental group) 
will receive bone cement without antibiotics. The type 
(brands) of bone cement will be determined according 
to each hospital’s standard protocol. All patients will 
receive systemic antibiotic prophylaxis according to the 
national guidelines.76 According to these guidelines, 
currently, patients should receive repeated doses of a first 
or second- generation cephalosporin or cloxacillin, or 
in the case of allergy, clindamycin; first dose should be 
administered 30–60 min preoperatively.76 Systemic antibi-
otic prophylaxis must constitute a maximum of four doses 
and be administered within the first 24 hours of surgery.
Quality control
All quality and safety aspects of this trial, including 
informed consent, inclusion and exclusion criteria, data 
quality as well as adverse events will be regularly moni-
tored by the trial steering committee and by the Norwe-
gian National Advisory Unit on Arthroplasty and Hip 
Fractures.
Data collection and assessment points
Patient recruitment and data collection will be expected 
to start in late 2020. Baseline and surgical- related infor-
mation will be collected on the day of surgery whereas 
PROMs data collected preoperative and at 1, 6 and 
10 years follow- up. Assessment will occur at predeter-
mined endpoints. Assessment on primary outcome and 
reports or presentations of preliminary results will be 
after completion of inclusion and full 1- year follow- up. 
First assessment will be when included patients have 
got a full 1- year follow- up. Latter assessments will be 
at 6, 10 and 20 years follow- up. The PROMs question-
naires will consist of general information (ie, education, 
smoking status, height and weight and diabetic status), 
Visual Analogue Scales for pain and satisfaction, Knee 
injury and Osteoarthritis Outcome Score for functional 
outcome, the 5- level Euroqol for health- related quality 
of life (HRQoL), University of California, Los Angeles 
activity score and Charnley score. Microbial pattern and 
resistance profiles of organisms cultured in subsequent 
revision will be followed up to death or emigration. The 
cost- effectiveness of ALBC use vs plain bone cement use 
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Data management, access and sharing
All this trial study data will be stored in the NAR Oracle 
database. On receipt of the data, the NAR personnel, 
blinded to the group allocation, will make a visual check 
of the data and query all missing, implausible and incon-
sistent data. During the study, the investigators have 
access to the trial data and statistic support from the NAR. 
Data generated by this trial will be made available after 
completion of patient inclusion and full 1- year follow- up, 
and will be available on reasonable request. Data access 
request will be reviewed by the Trial Steering Committee 
and by the Norwegian National Advisory Unit on Arthro-
plasty and Hip Fractures. Requestors will be required to 
sign the NAR data access agreement.
Outcomes
Primary outcome will be revision due to PJI at 1- year 
follow- up. Secondary outcomes will be:
 ► Risk of revision due to any reason including aseptic 
loosening at 1, 6, 10 and 20 years of follow- up.
 ► PROMs like function, pain, satisfaction and HRQoL 
at 1, 6 and 10 years of follow- up.
 ► Risk of changes in the microbial pattern and resist-
ance profiles of organisms cultured in subsequent 
revisions at 1, 6, 10 and 20 years of follow- up.
 ► Cost- effectiveness of routine ALBC versus plain bone 
cement use in primary TKA.
Statistical analysis
Baseline data
Statistical analyses will be conducted under the guid-
ance of biostatisticians at the NAR. Baseline data will be 
presented using descriptive statistics. χ2 test and indepen-
dent t- test will be used to investigate differences in base-
line characteristics between the two groups.
Outcome data
The power of this trial has been estimated based on non- 
inferiority design with the non- inferiority margin set to 
0.15%. The non- inferiority analysis will be based on the 
primary outcome. Data will be analysed according to 
the patient’s original treatment allocation in line with 
the intention- to- treat principles.77 78 One- year revision 
rate due to PJI will be estimated with the Kaplan- Meier 
method. Corresponding 95% CIs will be calculated to 
assess possible non- inferiority of plain bone cement 
against fixation with ALBC. Non- inferiority is indicated 
if the upper limit of the 95% CI for the absolute differ-
ence in risk of revision due to PJI does not exceed the 
defined inferiority margin of 0.15. Hazard ratios will be 
estimated using Cox regression analyses. Subanalyses for 
different age groups, sex, prosthesis brands, primary diag-
nosis, type and dose of antibiotic used in cement, cement 
brand, cement mixing and delivery systems, type, dose 
of parallel systemic antibiotic administration, operative 
side (right or left knee), surgical approach, duration of 
surgery and type of hospital (hospital volume) will be 
performed. The Outcome Measures in Rheumatology- 
Osteoarthritis Research Society International criteria 
for responder analyses will also be applied to calculate 
responder rates79 80 at 1, 6 and 10 years for comparing 
PROM scores between the two treatment groups.
The results will be presented with 95% CI. Missing data 
will be investigated for any relations to the outcomes of 
interest (missing at random). Missing items in PROMs 
will be handled in accordance with guidelines for each 
questionnaire.
Cost-effectiveness and cost–utility analysis
The cost- effectiveness analysis will compare costs of 
routine ALBC and plain bone cement use in primary 
TKA whereas cost–utility will compare changes in the 
PROM scores. Markov decision analysis will be used81 
(figure 2). The decision tree will represent the potential 
clinical course of patients in the ALBC versus plain bone 
cement. The periods for the cost- effectiveness and cost–
utility analyses will be from primary TKA surgery to a 1, 10 
and 20 years of follow- up.
Patient and public involvement
Patients' representative has been involved in this trial 
project from its planning phase. Patients' representative 
ia a member of the Norwegian National Advisory Unit 
on Arthroplastyand Hip Fractures’ Steering Committees. 
Any publications from this trial dataset will be reviewed 
by the trial steering committee before release. The final 
trial report will also be available on the NAR website. The 
results will be available to the public if necessary.
Ethics and dissemination
The trial has been approved by the Western Norway 
Regional Committees on Medical and Health Research 
Ethics (REK- Vest) (reference number: 2019/751/REK 
vest) dated: 21 June 2019. The NAR, Department of 
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Orthopaedic Surgery, Haukeland University Hospital is 
the responsible institution for this trial. The chief investi-
gator will coordinate dissemination of the trial data. The 
trial results will be reported following the Consolidated 
Standards of Reporting Trials Extension reporting guide-
line 2010 statement for non- inferiority trials. The trial 
results will be presented at national and international 
scientific conferences, and communicated to partici-
pating hospitals, patients and patient organisations, and 
will be published in peer- reviewed international journals. 
Any publications from this trial dataset will be reviewed by 
the trial steering committee before release. The final trial 
report will also be available on the NAR website.
DISCUSSION
R- RCT is a pragmatic trial that use existing registries as a 
platform for case identification, randomisation, clinical 
endpoint detection and outcome data collection. In other 
words, it combines a prospective randomised trial with the 
inclusiveness and efficiencies of a large- scale ‘real- world’ 
clinical registry.66 A standard randomised controlled 
trial (RCT) often has narrow inclusion criteria and low 
external validity, and often use surrogate endpoints to 
achieve adequate power within the scheduled follow- up. 
Observational studies have a high external validity, but 
are limited by selection bias and confounding. R- RCT has 
been successfully implemented in the Swedish Angiog-
raphy and Angioplasty Register65 and has been described 
as a new paradigm within clinical trials.66 By randomly 
assigning patients in a clinical quality registry, an R- RCT 
combines the advantages of a standard prospective RCT 
with a large- scale registry study. Most importantly, R- RCT 
is cost- effective and time- effective, using established 
follow- up routines and infrastructure for data registra-
tion.82 The work load on the patient and the surgeon is 
minimal, and all follow- up is done electronically via web- 
based solutions. The NAR is a well- established register 
with high national coverage and good response rate.68
If, in the contrary to our hypothesis, the plain bone 
cement is non- inferior to the ALBC, with regards to PJI, 
this trial finding will go against the current practice of 
routine use of ALBC in primary TKA in Norway. Changing 
such established treatment and implementing routine 
use of plain bone cement may be a challenge. However, 
if routine use of ALBC is associated with a reduced risk 
of PJI and with minor impact on bacterial resistance, 
PROMs and costs, the well- established use of prophylactic 
ALBC in primary arthroplasty will be supported. Finally, 
the current trial will provide the framework for future 
pragmatic R- RCT within the Norwegian orthopaedic 
registries.
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FORESPØRSEL OM DELTAKELSE I FORSKNINGSPROSJEKTET 
[ANTIBIOTIKA I BEINSEMENT VED KNEPROTESEKIRURGI FOR Å FOREBYGGE 
LEDDPROTESEINFEKSJON. EN REGISTER BASERT MULTISENTER 
RANDOMISERT KONTROLLERT STUDIE] 
Dette er et spørsmål til deg om å delta i et forskningsprosjekt for å sammenligne sementert 
totalprotese i kne med eller uten antibiotika i beinsementen.   
Du skal opereres med en kneprotese. Kneprotese er en etablert behandling med gode 
resultater for de aller fleste pasienter. Operasjonen innebærer at man setter inn et kunstig 
kneledd av plast og metall som festes med beinsement. En av de vanligste årsakene til 
reoperasjon er infeksjon. 
Den infeksjonsforebyggende effekten av antibiotika i beinsement ved primær totalprotese i 
kne er utilstrekkelig dokumentert. I de fleste Europeiske land inkludert Norge er bruk av 
antibiotika i beinsement i rutinemessig bruk i motsetning til i USA hvor antibiotika i 
beinsement ikke er godkjent i bruk ved vanlig kneprotesekirurgi. Det vil være uheldig å bruke 
antibiotika i sementen dersom det ikke hindrer infeksjoner da antibiotika kan føre til 
motstandsdyktige bakterier. Du vil uansett få vanlig antibiotika i blodet under operasjonen 
etter nasjonale retningslinjer. Denne studien har som mål å vise om antibiotika i beinsement 
reduserer forekomsten av infeksjon etter primær kneprotese. Pasienter som gjennomgår 
primær totalprotese i kne ved alle sykehusene i Norge vil bli inkludert og ved loddtrekning 
avgjøres det om du skal opereres med antibiotika i beinsement eller vanlig beinsement uten 
antibiotika. Det er kirurgen som bestemmer hvilke type beinsement (med eller uten 
antibiotika) du får dersom du ikke ønsker å delta i studien. Vi vil også undersøke hvilken 
metode som gir minst sykelighet, komplikasjoner og reoperasjoner. Livskvalitet, smerter, 
funksjon og tilfredshet vil også bli vurdert. 
HVA INNEBÆRER DELTAKELSE I STUDIEPROSJEKTET? 
Studien innebærer ingen ekstra belastning for deg. Kirurgen vil like før operasjonen gjennom 
en datagenerert loddtrekning (randomisering) avgjøre om du skal ha antibiotika i sementen 
eller ikke. Du skal følge rutinemessig oppfølging ved ditt sykehus. For å kunne delta i denne 
studien må du både gi skriftlig tillatelse til å bli registrert i Nasjonalt register for leddprotese 
og til deltagelse i denne studien. En eventuell reoperasjon (ny operasjon i samme kne) vil din 
kirurg melde til Nasjonalt register for leddproteser. 
HÅNDTERING AV OPPLYSNINGER OG PERSONVERN 
Deltagelse er frivillig, og du kan trekke deg fra studien, også etter operasjon. Dersom du 
velger ikke å delta i studien, vil dette ikke ha noen innvirkning på din behandling ved 
sykehuset, og du vil bli operert etter vanlig rutine ved ditt sykehus. 
De opplysninger og data som framkommer gjennom studien vil samles og databehandles.  
Dataene tas fra det som er registrert i Nasjonalt register for leddprotese om deg og din 
behandling. I registeret skal det samles opplysninger om fødselsnummer, diagnose, årsak til 
operasjon, medikamentbruk og bakterieprøver i forbindelse med operasjonen, og 
operasjonstekniske opplysninger. De samme opplysningene samles inn dersom du må 
gjennomgå en ny operasjon i samme kne. Denne informasjonen samles inn ved at kirurgen 
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like etter operasjonen fyller ut et skjema med opplysningene nevnt foran og sender det til 
Nasjonalt register for leddproteser. 
Du vil bli bedt om å fylle ut et skjema med spørsmål om din egenopplevde livskvalitet og 
leddfunksjon før operasjonen. Vi spør også om høyde, vekt, aktivitetsnivå, utdanningsnivå, 
alkoholbruk og om du røyker. Vi ber også om tillatelse til å kontakte deg for utfylling av 
tilsvarende evalueringsskjema 1, 6 og 10 år etter operasjonen.   
Studien er et samarbeidsprosjekt mellom alle norske sykehus. Alle opplysningene vil bli 
behandlet konfidensielt. Prosjektet avsluttes år 2034, etter minst 10 års oppfølging av alle 
pasienter, og randomiseringsnøkkelen vil da anonymiseres. Data vil beholdes i det Nasjonale 
registeret så lenge de har nødvendige godkjenninger til drift. 
Opplysningene som registreres om deg lagres elektronisk og skal kun brukes slik som beskrevet i 
denne informasjonen. Alle opplysninger er sikret mot innsyn fra uvedkommende. Direkte 
identifiserbare opplysninger, herunder navn, fødselsnummer eller andre personentydige 
kjennetegn, lagres adskilt fra de øvrige opplysningene på en forskningsserver i Helse-Bergen. En 
kode knytter deg til dine opplysninger gjennom en navneliste. Bare de to prosjektlederne har 
tilgang til navnelisten og kan finne tilbake til deg. Resultater fra studien skal publiseres på 
fagmøter og i nasjonale og internasjonale medisinske tidsskrifter. Resultater basert på analyse fra 
studien vil ikke kunne tilbakeføres til enkeltindivider.  
MULIGE FORDELER OG ULEMPER 
Det er en teoretisk mulighet for at pasienter som blir randomisert til behandling med sement 
uten antibiotika kan ha høyere risiko for å få proteseinfeksjon. Dette vet vi imidlertid ikke. På 
den annen side kan pasienter som får antibiotika i sement ha risiko for å utvikle 
motstandsdyktige bakterier, få allergisk reaksjon og bivirkninger av antibiotika i sementen.  
FRIVILLIG DELTAKELSE OG MULIGHET FOR Å TREKKE SITT SAMTYKKE 
Det er frivillig å delta i prosjektet. Dersom du ønsker å delta, undertegner du forespørsel om 
deltagelse i Nasjonalt register for leddproteser. Du kan når som helst og uten å oppgi noen 
grunn trekke ditt samtykke. Dette vil ikke få konsekvenser for din videre behandling. Dersom 
du trekker deg fra studieprosjektet, kan du kreve å få slettet innsamlede opplysninger. Hvis 
du senere ønsker å trekke deg kan du henvende deg til Nasjonalt register for leddproteser, 
Helse-Bergen HF, Ortopedisk klinikk, Haukeland universitetssjukehus, Møllendalsbakken 11, 
5021 Bergen. Telefon 55 97 37 42 / 55 97 37 43 eller e-post nrl@helse-bergen.no. 
HVA SKJER MED INNSAMLETE OPPLYSNINGENE OM DEG?  
Dine opplysninger blir registrert i Nasjonalt register for leddproteser. 
GODKJENNING 
Regional komité for medisinsk og helsefaglig forskningsetikk har vurdert prosjektet, og har 
gitt forhåndsgodkjenning: 2019/751/REK vest 
Etter ny personopplysningslov er Direktøren i Helse-Bergen dataansvarlig og har et 
selvstendig ansvar for å sikre at behandlingen av dine opplysninger har et lovlig grunnlag.  
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Dette prosjektet har rettslig grunnlag i EUs personvernforordning art. 6(1)(e) («oppgave i 
allmennhetens interesse») og art. 9(2)(j) («forskning»), sammen med bestemmelser i 
helseforskningsloven som rettsgrunnlag for databehandling. 
Du har rett til å klage på behandlingen av dine opplysninger til Datatilsynet.  
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